EN KR
EN KR
Linkedin Facebook

About Us

Syntekabio is an AI new drug development company
based on genomic big data

History

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

2023

9
  • Completion of the AI Bio-Supercom Center (Daejeon Dunjok District)

2022

12
  • Launch of STB CLOUD services in the United States
10
  • Launch of STB CLOUD services in KOREA
5
  • Relocation of the main office to Expo Tower 1903, Expo-ro 1, Yuseong-gu, Daejeon.

2021

11
  • Signed MOU with JW Pharmaceutical for development of innovative new drug
8
  • Signed strategic MOU with KT to build an AI supercomputer center
4
  • Purchased a site for construction of AI Supercomputing Center (Dungok District, Daejeon, South Korea)
3
  • Signed MOU with GL PharmTech
  • Signed Strategic Partnership Agreement with SLS Bio for joint establishment of immune monitoring assays
1
  • Signed Joint Research Agreement with Hanmi Science for COVID-19 drug repositioning
  • Invited to JP Morgan Healthcare Conference

2020

12
  • KR patent registered (composition patent for treating SARS-CoV-2 infection disease)
9
  • Signed MOU with KIMCo, Naver Business Platform, and AI Center
7
  • Signed MOU with Ajou University
6
  • Signed Joint R&D Agreement with KRIBB for COVID19 drug repositioning project
  • Selected as ‘Excellent Case of DNA (Data · Network · AI) Innovation Company in June 2020 ‘ by the Ministry of Science and ICT
5
  • Presented preclinical results of STB-C017 at AACR 2020
3
  • Signed Joint Research Agreement with Chungnam National University Hospital for collaboration on precision medicine
2
  • Signed MOU with Arctoris (UK)
1
  • Invited to JP Morgan Healthcare Conference
  • Signed Joint R&D Agreement with LegoChem Biosciences for AI drug discovery

2019

12
  • Listed on the KOSDAQ
6
  • Closed series C funding round led by Yuhan Corporation, Saehan Venture Capital, and Timewise (19.7B KRW)
5
  • Signed MOU with SCM Life Science
  • Established In silico Clinical Research Center (Daejeon, South Korea)
3
  • In-licensing of immune-oncology drug candidate (jointly discovered with CJ Healthcare)
1
  • Invited to JP Morgan Healthcare Conference
  • 2018
  • 2017
  • 2016
  • 2015

2018

12
  • Genetic Integration Core Technology Paper (BMC Bioinformatics 2018)
  • Collaboration contract for the Precision Medical Center of 'Yonsei Severance Hospital' (disease)
11
  • Joint Research Agreement with 'JW Pharmaceutical' (Preditive Biomarker)
6
  • New drug development model based on deep learning CDRscan POC thesis (Sci Rep 2018)
  • Genetic Variation Detection Algorithm ADIscan Verification Paper (Nucleic Acid Res 2018)
5
  • Joint Study on the Use of Big Data-Based AI with 'JW Pharmaceutical'
  • SeriesB Investment Attraction(12 billion won, smilegate · KDB Bank)
  • Collaboration contract of the Medical Center of 'Inha University Hospital' (cancer disease)
4
  • Agreements with the 'Naver Business Platform'
  • Joint research and collaboration MOUs with 'yuhan corporation'

2017

12
  • Contract of Research Services with 'CJ Healthcare' (Finding new active substance)
11
  • Joint study MOU with 'Yonsei Severance Hospital'
8
  • Journal of Clinical Verification for NGS Examination of Rare Diseases(Sci rep 2017)
6
  • KFDA WS GMP Certification (KTC-CAB-179288)
3
  • HLAscan Accuracy Verification Paper (BMC Bioinformatics 2017)
2
  • Inha University Hospital Precision Medicine Inititive MOU

2016

11
  • Joint research contract for new drugs with 'Kainos Medicine' and Parkinson's disease
10
  • Strategic business alliance MOU with 'Oracle Medical'
  • Chronic Disease Management joint research MOU with 'Huray Positive'
9
  • Parkinson Disease new drug joint research MOU with 'Kainosmed'
8
  • Strategic collaboration3 partnership MOU with 'Toolgen'
6
  • Obtained 'New Excellent Technology' related to genetic disease screening
  • SeriesA Investment Attraction(6 billion won, Altos Ventures, etc.)
1
  • Registered as genetic testing agency of Korea Centers for Disease Control and Prevention

2015

11
  • Introduction of Dx NGS equipment permitted by Ministry of food and drug
9
  • Colorectal cancer/ breast cancer market technology transfer with KIST theragnosis research team
8
  • Moved to head office to Daejeon Migeon Techno World II
  • Established Seoul Business Center and Cheongju Supercom Center
2
  • PMAP (Personal Genomic Map) Automatically Generated Beta Version Completed
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009

2014

4
  • Selected as Research Instutute by Electronics and Telecommunications Research Institute (ETRI)
3
  • Konkuk University Hospital & Konkuk Medical Graduate School BK21 Business team MOU

2013

12
  • Selected as '2020 Future 100 Technology and leaders'
4
  • Technology/ sales cooperation MOU with SLS medical diagnostic testingcompany.
  • RVR DBMS / Search System US Patent Office Registration Decision

2012

2
  • Completion of Genome Analysis Platform (NGS-pL)
1
  • Integrated genome integration service of next-generation personalized medical genome project team

2011

8
  • Next-Generation Personalized Medical Genome Project Consolidation Service
4
  • Established research center (Post-OMICS)

2010

7
  • Establizhed business headquarter at Silicon Valley, CA, USA.
6
  • Moved to Korea Institute of Science and Technology venture center

2009

12
  • Echnology Guarantee Fund Venture Certification
10
  • Changed company name and CEO: Syntekabio Inc.
8
  • Established. Yoobiori

send us your inquiry

SUBMIT
SUBMIT